Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

ICI-118630

Known as: ICI 118630, ICI118630 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummarySeventeen patients with advanced prostatic cancer were treated with the gonadotrophin-releasing hormone analogue DSer (tBU… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
1996
1996
Clinical and pathological changes of the mammary gland have been studied in 64 women affected by symptomatic Benign Breast… Expand
1987
1987
The antitumor effect and safety and endocrinological effect of a depot formulation of luteinizing hormone-releasing hormone (LH… Expand
1986
1986
A single shot of 250 micrograms LH-RH agonist, ICI 118630 (Zoladex), was subcutaneously administered to four healthy male… Expand
Highly Cited
1986
Highly Cited
1986
Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
1984
Highly Cited
1984
Twenty two patients with advanced carcinoma of the prostate have been treated for up to 3 months with the slow-release (depot… Expand
1984
1984
The influence of the LH-RH agonist ICI 118630 on circulating levels of the pituitary gonadotrophins LH and FSH and the gonadal… Expand
Highly Cited
1983
Highly Cited
1983
8 patients with advanced prostatic carcinoma were treated with the luteinising-hormone releasing-hormone agonist, ICI 118630, for… Expand
1981
1981
Direct inhibitory effects of LHRH and an LHRH agonist (ICI-118630) on FSH-controlled steroidogenic processes in ovarian granulosa… Expand
Highly Cited
1979
Highly Cited
1979
Experiments were undertaken with DMBA-induced mammary tumours of the rat to determine the anti-tumour properties of a new and… Expand
  • figure 1
  • figure 2
  • figure 3
  • table I
  • figure 4